These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 14060969)
21. In vivo models of prostate cancer metastasis to bone. Singh AS; Figg WD J Urol; 2005 Sep; 174(3):820-6. PubMed ID: 16093963 [TBL] [Abstract][Full Text] [Related]
22. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Higano CS Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412 [TBL] [Abstract][Full Text] [Related]
23. [COMPARATIVE INVESTIGATION OF THE DIFFERENT SERO-HUMORAL CHANGES IN CARCINOMA OF THE PROSTATE. EFFECTS INDUCED BY THE ADMINISTRATION OF ESTROGENS]. STRADAJOLI G; GALLIVANONE A Arch Ital Urol; 1963 Dec; 36():275-85. PubMed ID: 14114462 [No Abstract] [Full Text] [Related]
24. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer. Kikuchi E; Nakashima J; Ishibashi M; Ohigashi T; Oya M; Nakagawa K; Miyajima A; Murai M Urology; 2006 Aug; 68(2):371-5. PubMed ID: 16904455 [TBL] [Abstract][Full Text] [Related]
25. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249 [TBL] [Abstract][Full Text] [Related]
26. Variations in the phosphatase activity in two patients with cancer of the prostate and pernicious anaemia. Andersen KF Dan Med Bull; 1965 Oct; 12(6):171-2. PubMed ID: 5851378 [No Abstract] [Full Text] [Related]
27. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895 [TBL] [Abstract][Full Text] [Related]
28. Metastases of prostate cancer express estrogen receptor-beta. Lai JS; Brown LG; True LD; Hawley SJ; Etzioni RB; Higano CS; Ho SM; Vessella RL; Corey E Urology; 2004 Oct; 64(4):814-20. PubMed ID: 15491740 [TBL] [Abstract][Full Text] [Related]
29. New generation of bisphosphonates: broad clinical utility in breast and prostate cancer. Rosen LS Oncology (Williston Park); 2004 May; 18(5 Suppl 3):26-32. PubMed ID: 15202585 [TBL] [Abstract][Full Text] [Related]
30. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases. Saad F; Markus R; Goessl C BJU Int; 2008 May; 101(9):1071-5. PubMed ID: 18070191 [TBL] [Abstract][Full Text] [Related]
31. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates. Green JR Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701 [TBL] [Abstract][Full Text] [Related]
33. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463 [TBL] [Abstract][Full Text] [Related]
34. Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer. Bobinac D; Marić I; Zoricić S; Spanjol J; Dordević G; Mustać E; Fuckar Z Croat Med J; 2005 Jun; 46(3):389-96. PubMed ID: 15861517 [TBL] [Abstract][Full Text] [Related]
35. Current trials using bone-targeting agents in prostate cancer. Tu SM; Lin SH Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481 [TBL] [Abstract][Full Text] [Related]
36. [OSTEOLYTIC FORMS OF CANCER OF THE PROSTATE]. RAVAULT PP; LEJEUNE E; BOUVIER M; BERTRAND JN; TOURNIAIRE J Montp Med; 1963; 64():45-62. PubMed ID: 14186190 [No Abstract] [Full Text] [Related]